Current therapies and future perspectives in subacute sclerosing panencephalitis

References

• Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. Dev. Med. Child Neurol.52(10), 901–907 (2010).
   PubMedGoogle Scholar
• Nihei K. Epidemiological aspects of SSPE. Nihon Rinsho.65(8), 1460–1465 (2007).
   PubMedGoogle Scholar
• Centers for disease control and prevention (CDC). Progress toward measles elimination – European region, 2005–2008. MMWR Morb. Mortal. Wkly Rep.58(6), 142–145 (2009).
   PubMedGoogle Scholar
• Centers for disease control and prevention (CDC). Increased transmission and outbreaks of measles – European region. MMWR Morb. Mortal. Wkly Rep.60, 1605–1610 (2011).
   PubMedGoogle Scholar
• Centers for disease control (CDC). Measles: United States, January–May 20, 2011. MMWR Morb. Mortal. Wkly Rep.60(20), 666–668 (2011).
   PubMedGoogle Scholar
• Bellini WJ, Rota JS, Lowe LE et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J. Infect. Dis.192(10), 1686–1693 (2005).
   PubMedGoogle Scholar
• Centers for disease control (CDC). Subacute sclerosing panencephalitis surveillance – United States. MMWR Morb. Mortal. Wkly Rep.31(43), 585–588 (1982).
   PubMedGoogle Scholar
• Zilber N, Rannon L, Alter M, Kahana E. Measles, measles vaccination, and risk of subacute sclerosing panencephalitis (SSPE). Neurology33(12), 1558–1564 (1983).
   PubMedGoogle Scholar
• Manning L, Laman M, Edoni H, Mueller I, Karunajeewa HA. Subacute sclerosing panencephalitis in Papua New Guinean children: the cost of continuing inadequate measles vaccine coverage. PLoS Negl. Trop. Dis.5(1), e932 (2011).
   PubMedGoogle Scholar
• Zilber N, Kahana E. Environmental risk factors for subacute sclerosing panencephalitis (SSPE). Acta Neurol. Scand.98(1), 49–54 (1998).
   PubMedGoogle Scholar
• Baczko K, Liebert UG, Billeter M, Cattaneo R, Budka H, ter Meulen V. Expression of defective measles virus genes in brain tissues of patients with subacute sclerosing panencephalitis. J. Virol.59(2), 472–478 (1986).
   PubMed Web of Science ®Google Scholar
• Allen IV, McQuaid S, McMahon J, Kirk J, McConnell R. The significance of measles virus antigen and genome distribution in the CNS in SSPE for mechanisms of viral spread and demyelination. J. Neuropathol. Exp. Neurol.55(4), 471–480 (1996).
   PubMedGoogle Scholar
• Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J. Infect. Dis.170(Suppl. 1), S24–S31 (1994).
   PubMedGoogle Scholar
• Hara T, Yamashita S, Aiba H et al. Measles virus-specific T helper 1/T helper 2-cytokine production in subacute sclerosing panencephalitis. J. Neurovirol.6(2), 121–126 (2000).
   PubMed Web of Science ®Google Scholar
• Fukuya H, Ohfu M, Tomoda Y, Nibu K, Ichiki S, Midsudome A. [A case of subacute sclerosing panencephalitis developing 8 years after immunosuppressive treatment for acute lymphocytic leukemia]. No To Hattatsu24(1), 60–64 (1992).
   PubMedGoogle Scholar
• Herguner MO, Altunbasak S, Baytok V. Patients with acute, fulminant form of SSPE. Turk. J. Pediatr.49(4), 422–425 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhne Simmonds M, Brown DW, Jin L. Measles viral load may reflect SSPE disease progression. Virol. J.3, 49 (2006).
   PubMedGoogle Scholar
• Hayashi M, Arai N, Satoh J et al. Neurodegenerative mechanisms in subacute sclerosing panencephalitis. J. Child Neurol.17(10), 725–730 (2002).
   PubMed Web of Science ®Google Scholar
• Garg RK. Subacute sclerosing panencephalitis. Postgrad. Med. J.78, 63–70 (2002).
   PubMed Web of Science ®Google Scholar
• Jabbour JT, Garcia JH, Lemmi H, Ragland J, Duenas DA, Sever JL. Subacute sclerosing panencephalitis. A multidisciplinary study of eight cases. JAMA207(12), 2248–2254 (1969).
   PubMed Web of Science ®Google Scholar
• Risk WS, Haddad FS. The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East. Arch. Neurol.36(10), 610–614 (1979).
   PubMedGoogle Scholar
• Anlar B, Yalaz K. Prognosis in subacute sclerosing panencephalitis. Dev. Med. Child Neurol.53(10), 965 (2011).
   PubMedGoogle Scholar
• Chung BH, Ip PP, Wong VC, Lo JY, Harding B. Acute fulminant subacute sclerosing panencephalitis with absent measles and PCR studies in cerebrospinal fluid. Pediatr. Neurol.31(3), 222–224 (2004).
   PubMedGoogle Scholar
• Yilmaz D, Aydin OF, Senbil N, Yuksel D. Subacute sclerosing panencephalitis: is there something different in the younger children? Brain Dev.28(10), 649–652 (2006).
   PubMedGoogle Scholar
• Grippo J, Cáceres L, Asís A, Grippo T, Ruprecht B, López M. Subacute sclerosing panencephalitis: fulminant form. Rev. Neurol.36(6), 536–539 (2003).
   PubMedGoogle Scholar
• Ekici B, Çal??kan M, Tatl? B, Aydinli N, Özmen M. Rapidly progressive subacute sclerosing panencephalitis presenting with acute loss of vision. Acta Neurol. Belg.111(4), 325–327 (2011).
   PubMedGoogle Scholar
• Wiranowska-Stewartv M, Hadden JW. Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production. Int. J. Immunopharmacol.8(1), 63–69 (1986).
   PubMedGoogle Scholar
• Tsang PH, Sei Y, Bekesi JG. Isoprinosine-induced modulation of T-helper-cell subsets and antigen-presenting monocytes (Leu M3+Ia+) resulted in improvement of T- and B-lymphocyte functions, in vitro in ARC and AIDS patients. Clin. Immunol. Immunopathol.45(2), 166–176 (1987).
   PubMedGoogle Scholar
• Jones CE, Dyken PR, Huttenlocher PR, Jabbour JT, Maxwell KW. Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients. Lancet8(1), 1034–1037 (1982).
   Google Scholar
• Silverberg R, Brenner T, Abramsky O. Inosiplex in the treatment of subacute sclerosing panencephalitis. Arch. Neurol.36(6), 374–375 (1979).
   PubMedGoogle Scholar
• Huttenlocher PR, Mattson RH. Isoprinosine in subacute sclerosing panencephalitis. Neurology29(6), 763–771 (1979).
   PubMedGoogle Scholar
• Fukuyama Y, Nihei K, Matsumoto S et al. Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis – a multi-institutional collaborative study – the inosiplex-SSPE research committee. Brain Dev.9(3), 270–282 (1987).
   PubMedGoogle Scholar
• Dyken PR, Swift A, DuRant RH. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann. Neurol.11(4), 359–364 (1982).
   PubMedGoogle Scholar
• Gascon GG. International consortium on subacute sclerosing panencephalitis. Randomized treatment of inosiplex versus combined inosiplex and intra-ventricular interferon-α in subacute sclerosing panencephalitis (SSPE): international multicentre study. J. Child Neurol.18(12), 819–832 (2003).
   PubMedGoogle Scholar
• Vilcek J, Sen G. Interferons and other cytokines. In: Fields Virology (3rd Edition). Lippincott-Raven, PA, USA, 375–399 (1996).
   Google Scholar
• Nakagawa M, Michihata T, Yoshioka H et al. Intrathecal administration of human leukocyte interferon to a patient with subacute sclerosing panencephalitis. Acta Paediatr. Scand.74(2), 309–310 (1985).
   PubMedGoogle Scholar
• Panitch HS, Gomez-Plasclencia J, Norris KFW et al. Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon. Neurology36(4), 562–546 (1986).
   PubMedGoogle Scholar
• Yalaz K, Anlar B, Oktem F et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology42(3 Pt 1), 488–491 (1992).
   PubMedGoogle Scholar
• Anlar B, Yalaz K, Oktem F, Köse G. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular α-interferon. Neurology48(2), 526–528 (1997).
   PubMedGoogle Scholar
• Floris S, Ruuls SR, Wierinckx A et al. Interferon-β directly influences monocyte infiltration into the central nervous system. Neuroimmunology27(1–2), 69–79 (2002).
   Google Scholar
• Anlar B, Soylemezoglu E, Aysun S et al. Tissue inflammatory response in subacute sclerosing panencephalitis (SSPE). Child Neurol.16(12), 895–900 (2001).
   Google Scholar
• Anlar B, Aydin OF, Guven A, Sonmez FM, Kose G, Herguner O. Retrospective evaluation of interferon-β treatment in subacute sclerosing panencephalitis. Clin. Ther.26(11), 1890–1894 (2004).
   PubMedGoogle Scholar
• Trottier C, Chabot S, Mann KK et al. Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathways. Antiviral Res.80(1), 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• Trottier C, Colombo M, Mann KK, Miller WH, Ward BJ. Retinoids inhibit measles virus through a Type 1 IFN-dependent bystander effect. FASEB J.23(9), 3203–3212 (2009).
   PubMedGoogle Scholar
• Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. Cochrane Database Syst. Rev.4, CD001479 (2005).
   Google Scholar
• Gungor S, Olmez A, Firat PA, Haliloğlu G, Anlar B. Serum retinol and β-carotene levels in subacute sclerosing panencephalitis. J. Child Neurol.22(2), 341–343 (2007).
   PubMedGoogle Scholar
• Gürer YKY, Kükner Ş, Sarica B. Intravenous y-globulin treatment in a patient with subacute sclerosing panencephalitis. Pediatr. Neurol.14(1), 72–74 (1996).
   PubMedGoogle Scholar
• Serdaroglu G, Kutlu A, Tekgul H, Tutuncuoglu S. Subacute sclerosing panencephalitis: a case with fulminant course after ACTH. Pediatr. Neurol.31(1), 67–70 (2004).
   PubMedGoogle Scholar
• Shimizu T, Matsuishi T, Iwamoto R et al. Elevated levels of anti-CD9 antibodies in the cerebrospinal fluid of patients with subacute sclerosing panencephalitis. J. Infect. Dis.185(9), 1346–1350 (2002).
   PubMedGoogle Scholar
• Titomanlio L, Soyah N, Guerin V et al. Rituximab in subacute sclerosing panencephalitis. Eur. J. Paediatr. Neurol.11(1), 43–45 (2007).
   PubMedGoogle Scholar
• Gil J, Szmigielski S, Jeljaszewicz J, Pulverer G. Immunotherapy of chronic active viral hepatitis B with propionibacterium granulosum KP-45 (a 5-year follow-up report). Hepatogastroenterology39(4), 325–329 (1992).
   PubMed Web of Science ®Google Scholar
• Sobczyk W, Kulczycki J, Iwińska B et al. Propionibacterium granulosum KP-45 in the treatment of subacute sclerosing panencephalitis. Psychiatr. Neurol. Med. Psychol. (Leipz).41(6), 344–351 (1989).
   PubMedGoogle Scholar
• Jakubowska T, Luczywek E, Sobczyk W, Pi?kowska E. Changes of cognitive and emotional processes during immunostimulatory treatment in subacute sclerosing panencephalitis. Neurol. Neurochir. Pol.27(1), 45–53 (1993).
   PubMedGoogle Scholar
• Sobczyk W, Pi?kowska E, Iwińska-Buksowicz B, Milewska D. Selective problems from catamnestic studies of SSPE patients (1980–1989). Neurol. Neurochir. Pol.28(1 Suppl. 1), 67–78 (1994).
   PubMedGoogle Scholar
• Sobczyk W, Kulczycki J, Pi?kowska E, Iwińska B, Milewska D, Szmigielski S. Comparison of the results of the treatment of patients with SSPE using various immunomodulating preparations. Neurol. Neurochir. Pol.25(5), 626–633 (1991).
   PubMedGoogle Scholar
• Murphy MF. In vitro inhibition of subacute sclerosing panencephalitis virus by the antiviral agent ribavirin. J. Infect. Dis.138(2), 249–251 (1978).
   PubMedGoogle Scholar
• Honda Y, Hosoya M, Ishii T, Shigeta S, Suzuki H. Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters. Antimicrob. Agents Chemother.38(4), 653–655 (1995).
   Google Scholar
• Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon α-2b and ribavirinfor chronic hapatitis C in patients with aprivious non-response or non-sustained response to interferon alone. J. Med. Virol.46(1), 43–47 (1995).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Hosoya M, Kimura K et al. The cooperative effect of interferon-α and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antiviral Res.37(1), 29–35 (1998).
   PubMedGoogle Scholar
• Tomoda A, Nomura K, Shiraishi S, Miike T, Hamada A, Hosoya M. [Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan]. No To Hattatsu35(4), 321–326 (2003).
   PubMedGoogle Scholar
• Hosoya M, Mori S, Tomoda A et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob. Agents Chemother.48(12), 4631–4635 (2004).
   PubMedGoogle Scholar
• Sato K, Nakagawa E, Nonoda Y et al. [Serious complications of intraventricular interferon-α and ribavirin in the treatment of subacute sclerosing panencephalitis]. No To Hattatsu41(3), 224–228 (2009).
   PubMedGoogle Scholar
• Burke JD, Fish EN. Antiviral strategies: the present and beyond. Curr. Mol. Pharmacol.2(1), 32–39 (2009).
   PubMedGoogle Scholar
• Robertson WC, Clark DB, Markesbery WR. Review of 38 cases of subacute sclerosing panencephalitis: effect of amantadine on the natural course of the disease. Ann. Neurol.8(4), 422–425 (1980).
   PubMedGoogle Scholar
• Nasirian A, Ashrafi MR, Nasrabady ES. Use of a-interferon, amantadine and isoprinosine in subacute sclerosing panencephalitis (SSPE): comparing the effectiveness. Iran J. Child Neurol.2(2), 27–32 (2007).
   Google Scholar
• Hayashi T, Ichiyama T, Nishikawa M, Furukawa S. Carbamazepine and myoclonus in SSPE subacute sclerosing encephalitis. Pediatr. Neurol.14(4), 346 (1996).
   PubMedGoogle Scholar
• Yiğit A, Sarikaya S. Myoclonus relieved by carbamazepine in subacute sclerosing panencephalitis. Epileptic Disord.8(1), 77–80 (2006).
   PubMedGoogle Scholar
• Becker D, Patel A, Abou-Khalil BW, Pina-Garza JE. Successful treatment of encephalopathy and myoclonus with levetiracetam in a case of subacute sclerosing panencephalitis. J. Child Neurol.24(6), 763–767 (2009).
   PubMedGoogle Scholar
• Anlar B, Soylemezoglu F, Elibol B et al. Apoptosis in brain biopsies of subacute sclerosing panencephalitis patients. Neuropediatrics30(5), 239–242 (1999).
   PubMedGoogle Scholar
• Perovic S, Pialoglou P, Schröder HC, Pergande G, Müller WE. Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur. J. Pharmacol.317(1), 157–164 (1996).
   PubMedGoogle Scholar
• Tatli B, Ekici B, Ozmen M. Flupirtine may stop the progressive course of subacute sclerosing panencephalitis. Med. Hypotheses75(6), 576–577 (2010).
   PubMedGoogle Scholar
• Hannon GJ. RNA interference. Nature418(6894), 244–251 (2002).
   PubMed Web of Science ®Google Scholar
• Downward J. RNA interference. BMJ328(7450), 1245–1248 (2004).
   PubMed Web of Science ®Google Scholar
• Otaki M, Sada K, Kadoya H, Nagano-Fujii M, Hotta H. Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference. Antiviral Res.70(3), 105–111 (2006).
   PubMedGoogle Scholar
• Reuter T, Weissbrich B, Schneider-Schaulies S, Schneider-Schaulies J. RNA interference with measles virus N-, P- and L-mRNAs efficiently prevents, and with matrix protein-mRNA enhances viral transcription. J. Virol.80(12), 5951–5957 (2006).
   PubMed Web of Science ®Google Scholar
• Zinke M, Kendl S, Singethan K et al. Clearance of measles virus from persistently infected cells by short hairpin RNA. J. Virol.83(18), 9423–9431 (2009).
   PubMedGoogle Scholar
• Watanabe A, Yoneda M, Ikeda F, Terao-Muto Y, Sato H, Kai C. CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J. Virol.84(9), 4183–4193 (2010).
   PubMed Web of Science ®Google Scholar
• Gallay PA. Cyclophilin inhibitors. Clin. Liver Dis.13(3), 403–417 (2009).
   PubMed Web of Science ®Google Scholar
• Makhortova NR, Askovich P, Patterson CE, Gechman LA, Gerard NP, Rall GF. Neurokinin-1 enables measles virus trans-synaptic spread in neurons. Virology362(1), 235–244 (2007).
   PubMedGoogle Scholar
• Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists – current prospects. Curr. Opin. Drug Discov. Dev.10(5), 613–621 (2007).
   PubMedGoogle Scholar
• Gokcil Z, Odabasi Z, Demirkaya S, Eroglu E, Vural O. α-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis. J. Neurol. Sci.162(1), 62–64 (1999).
   PubMedGoogle Scholar
• Gascon G, Yamani S, Crowell J et al. Combined oral isoprinosine–intraventricular α-interferon therapy for subacute sclerosing panencephalitis. Brain Dev.15(5), 346–355 (1993).
   PubMedGoogle Scholar